

FORT WORTH, Texas--(BUSINESS WIRE)--AMTC-- Bell Textron Inc., a Textron Inc. (NYSE: TXT) company, announced during the annual Air Medical Transport Conference (AMTC) 2026 the purchase order for a Bell 407GXi to HALO-Flight, further expanding the ability to deliver rapid, life-saving air medical transport to patients across South Texas. This aircraft marks the seventh IFR-equipped Bell 407GXi to soon join the HALO fleet, enhancing reliability and providing time-sensitive care across the region.

FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.


SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, following the close of trading. Halozyme will host a conference call on Thursday, November 5, 2026 at 1:30pm PT/4:30pm ET to discuss the results.

Five Strong Buy stocks stand out ahead of earnings, combining high operating margins, revenue growth and exposure to AI, healthcare, energy and digital payments.

Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.


HALO, GCT, LIND, PR and CVX stand out as relative strength picks amid market volatility, backed by strong price performance and upbeat earnings estimates.